Metrics
191,583 Downloads
Contact Share
heiDATA is an institutional repository for Open Research Data from Heidelberg University. It is managed by Heidelberg University's Research Data Unit, a joint institution of the University Library and the Computing Centre. If you are interested in publishing your data here, please have a look at our user guide and get in touch with us. Detailed information on heiDATA can be found in our service description.
Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

Advanced Search

2,981 to 2,990 of 9,014 Results
Vardarli_Suppl Fig 28.pdf
Vardarli_Suppl Fig 28.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 67.4 KB - MD5: 8f768c3ab7b25047e003722d31d43afb
Suppl. Fig. 28. Funnel plot for subgroups of ICI types trials investigating hyperthyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 29.pdf
Vardarli_Suppl Fig 29.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 70.3 KB - MD5: 492e9686bf659e65cd7f1254b3a85934
Suppl. Fig. 29. Galbraith plot for trials investigating hyperthyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 2.pdf
Vardarli_Suppl Fig 2.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 125.6 KB - MD5: 87bb45b21058e309b045d9c589b87c88
Suppl. Fig. 2. Forest plot for subgroups of ICI types trials investigating hypothyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 30.pdf
Vardarli_Suppl Fig 30.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 66.3 KB - MD5: 2192f7e8ff4483056f345ba7d03d8e05
Suppl. Fig. 30. Funnel plot for subgroups of ICI types trials investigating hyperthyroidism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 31.pdf
Vardarli_Suppl Fig 31.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 70.1 KB - MD5: 0855d76352930fe3135d6223717fdc27
Suppl. Fig. 31. Galbraith plot for trials investigating hyperthyroidism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 32.pdf
Vardarli_Suppl Fig 32.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 67.4 KB - MD5: f88edd9d1434d2e7a485b0046ef138cc
Suppl. Fig. 32. Funnel plot for trials investigating hypophysitis/hypopituitarism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 33.pdf
Vardarli_Suppl Fig 33.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 64.7 KB - MD5: ca104b25c915d8cc5ed5279e61a82df1
Suppl. Fig. 33. Funnel plot with trim-and-fill for trials investigating hypophysitis/hypopituitarism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 34.pdf
Vardarli_Suppl Fig 34.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 70.6 KB - MD5: 443bc4569f1231d2a43fc5d8673c139d
Suppl. Fig. 34. Galbraith plot for trials investigating hypophysitis/hypopituitarism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 35.pdf
Vardarli_Suppl Fig 35.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 64.1 KB - MD5: ba984fd679c86b272e1d13f3d8ad2365
Suppl. Fig. 35. Funnel plot for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 36.pdf
Vardarli_Suppl Fig 36.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 66.8 KB - MD5: 556e803b091dfed445b705972e835632
Suppl. Fig. 36. Funnel plot for subgroups of ICI types trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Add Data

Sign up or log in to create a dataverse or add a dataset.

Sign Up Log In
Share Dataverse

Share this dataverse on your favorite social media networks.

Link Dataverse
Reset Modifications

Are you sure you want to reset the selected metadata fields? If you do this, any customizations (hidden, required, optional) you have done will no longer appear.